Summary. In this paper the predictive value of molecular prognostic parameters for bladder cancer is discussed. DNA ploidy has additional prognostic value for grade 2 tumors, irrespective of stage, with aneuploid tumors having a poor prognosis. Overexpression of the epidermal growth factor receptor (EGFR) can be used as a prognostic factor for the group of superficial tumors. Both abnormal E-cadherin and retinoblastoma (RB) expression have additional prognostic value for invasive tumors. The exact predictive value for the superficial tumors needs further study. The results with respect to p53 are conflicting and its exact role especially in the progression of pTlg3 tumors has to be clarified. In view of the discordance concerning its prognostic value, c-erbB-2 overexpression also needs further study. It appears that at this moment only a few molecular markers seem to have potential prognostic value, but their precise clinical relevance has to be studied more extensively. In particular the value of progression markers in the superficial TCC needs more attention.
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Bladder cancer can present in a wide spectrum of clinical and pathological appearances. At the time of diagnosis, approximately two-thirds of bladder tumors are superficial transitional-cell carcinomas [TCC; pTa, pT1, or carcinoma in situ (pTis)] and one-third of them are invasive (pT2, pT3, pT4) or metastatic [44] . Most patients with superficial bladder cancers have a good prognosis; however, 10%-25% clinically progress to a more aggressive state, showing an increase in grade and/or infiltration into the muscle layer. To indicate the patients at risk, many investigators have tried to identify markers associated with progression from superficial to invasive or metastatic disease.
Cytogenetics studies have shown an association between chromosomal changes and carcinogenesis and disease progression. More recently, advances in the molecular approach to tumor biology have shown that oncogenesis and tumor progression are considered to be multistep processes in which the accumulation of the genetic alterCorrespondence to: J. A . M . V e t ations rather than their sequence is responsible for determining the tumor's biological properties [13] . This multistep process involves a number of genes, among which oncogenes, tumor-suppressor genes, and modulator genes play a crucial role [29] . Most of the gene products characterized thus far are part of molecular communication systems, e.g., growth factors [sis, epidermal growth factor (EGF)], growth factor receptors (EGFR, erb-B2), guanine triphosphate (GTP)-binding protein (ras), protein kinases (pp60°-sr°), DNA-binding protein/cell-cycle-control proteins [retinoblastoma (RB), p53], and cell-adhesion molecules (E-cadherin, invasion-suppressor gene). Protooncogenes are commonly activated by point mutation or amplification, and tumor-suppressor genes are commonly inactivated by point mutation, rearrangement, or deletion [6] . In this paper, the predictive value of molecular parameters for the progression of bladder cancer is discussed.
DNA ploidy and chromosomal changes in bladder cancer
Cellular DNA content can be measured either by flow cytometry or by densitometry analysis. Aneuploidy in bladder tumors has been extensively studied [30] , and aneuploidy correlates with a high propensity to progress to invasion and metastasis and with poor survival [7] . However, it should be noted that as most grade 1 tumors are diploid and most grade 3 tumors are aneuploid, cellular DNA content may be a differential prognostic marker only for grade 2 tumors. In a few studies the biological significance of aneuploidy in tumor progression has been considered. It has been hypothesized that tumor cells first acquire a tetraploid status, whereafter cells can evolve by chromosome loss without lethal effect [11, 17] . Thus, more aggressive clones could emerge at a higher rate in these tumors as compared with diploid tumors. For grade 2 tumors, in which both diploid and aneuploid tumors are observed, ploidy has additional prognostic value.
Conventional karyotype analyses have shown nonrandom changes in chromosomes 1, 5, 7, 9, and 11 in bladder cancer [1, 4, 18, 19, 46, 50, 56] . According to Gibas et al. [19] , monosomy of chromosome 9 is more prevalent in
Normal urothelioma 17p_~-~gls~T1 Y2-Y4 Hopman and co-workers [23, 24] used in situ hybridization to study chromosomal changes; this technique has enabled the study of numeric and structural chromosomal changes in nonmitotic cells. Using specific probes for chromosomes 1, 7, 9, and 11, abnormalities of all four chromosomes were found in some but not all tumors. These investigators were capable of confirming the prevalent loss of chromosome 9 in low-grade/low-stage TCC and they concluded that loss of chromosome 9 may be one of the primary events in the development of TCC.
The technique of restriction-fragment-length polymorphism (RFLP) has allowed an even more detailed analysis of chromosomal changes. Fearon et al. [14] demonstrated allelic loss of chromosome 1 lp in 40% of the informative invasive tumors examined. Tsai et al. [54] confirmed the loss of 1 lp and also demonstrated allelic loss on chromosome 17p and 9q in 63% and 67% of invasive tumors, respectively. Another study has shown that the loss of heterozygosity (LOH) of chromosome 17p is associated with high stage and grade [43] . Recently, Habuchi et al. [21] confirmed these results and added that markers on chromosome 13q and 3p were lost. The loss of 3p and 13q was associated with invasive tumors. Although the loss of 1 lp was more frequently associated with an invasive phenotype, this loss was detected in a considerable number (9/26, 35%) of noninvasive tumors. Therefore, these investigators conclude that the loss of 1 lp might generally occur at an earlier stage of tumor progression, before the loss of 3p, 13q, and 17p. This high rate of loss of llp in noninvasive tumors has not been shown in previous studies [43] , which can be explained by the more restricted area of chromosome llp studied. Recently it has been suggested that simultaneously occurring carcinoma in situ (CIS) and other TCCs do not share the same genetic defect with respect to loss of chromosomes 9q and 17p; 17p loss is associated with CIS, in which 9q loss is less often observed than in papillary tumors [39] .
The most important chromosomal changes found thus far in bladder cancer are summarized in Fig. 1 .
Although 9q loss is noted to occur generally early, it is important to emphasize that the accumulation of genetic events and not necessarily the sequence of these events determines progression. The exact biological role of these chromosomal aberrations and the genes involved is the subject of ongoing investigations.
Epidermal growth factor receptor
The interest in studying EGF and its receport was based on the finding of high EGF levels in urine. In 1984, Messing [37] reported that the growth and division of certain TCC cell lines responded to applied EGF. Several investigators have studied the EGF receptor (EGFR), the product of the c-erbB-1 gene, and found a good correlation between EGFR overexpression and both grade and stage [5, 38, 41] . The correlation between EGFR positivity and clinical outcome was studied immunohistochemically in 101 bladder tumors. EGFR overexpression appeared to be a significant prognostic factor for the whole group studied. The difference in survival observed between EGFR-positive and EGFR-negative tumor-bearing patients was not significant when the data from patients with muscle-invasive disease were analyzed separately. However, in patients with superficial TCC (pTa, pT1), EGFR overexpression is correlated with the recurrence rate, the time to recurrence, and tumor progression [40, 42] .
EGFR expression can be induced by overexpression of the H-ras gene. This has been found to occur at the protein and mRNA levels, and analysis of EGFR promoter/ enhancer sequences has revealed a putative AP-1 site that may possibly serve as a ras-responsive element [53] . These results suggest a role for either a normal or a mutated overexpression of H-ras in up-regulating the expression of EGFR.
EGFR gene amplification has been demonstrated by means of Southern-blot analysis in only 1 of 31 bladder tumors [5] . The c-erbB-2 gene is a human proto-oncogene located on chromosome 17 that encodes a transmembrane growth factor receptor with significant sequence homology to EGFR [61] . Amplification of the erb-B2 and EGFR genes was studied in carcinoma cells from human urinary bladder washings by the polymerase chain reaction. In this study, 4 of 47 bladder washings (all grade II/III patients) exhibited c-erbB-2 amplification and 2 of 47 wastings (grade III) showed EGFR amplification [35] . Gene amplification does not seem to be the mechanism for EGFR or c-erbB-2 overexpression. Zau et al. [63] found expression of the c-erbB-2 oncoprotein in 68% of tumors and in none of the controls. Sato et al. [48] showed c-erbB-2 oncoprotein expression to be correlated with tumor grade and survival. Multivariate analysis showed that c-erbB-2 expression was a prognostic factor independent of the grade and stage of the tumors. This suggested prognostic value of c-erbB-2 expression is in discordance with the results of another immunohistochemistry study done recently [32] . In this study, 99/249 (39%) of bladder tumors were found to be positive for c-erbB-2 oncoprotein. A correlation was found between c-erbB-2 expression, tumor grade, DNA aneuploidy, high S-phase fraction, and decreased survival. However, immunohistochemical demonstration of c-erbB-2 oncoprotein overexpression has no additional prognostic value over the previously established predictors of TCC. This discordance could be the result of the different antibodies or scoring systems used.
Thus, it can be concluded that for the group of superficial tumors, EGFR overexpression can be used as a prognostic marker. In view of the discordance concerning its prognostic value, c-erbB-2 overexpression needs further detailed attention.
P53 tumor-suppressor gene
The p53 gene is considered the tumor-suppressor gene on chromosome 17p, since in cancer development, frequently one of the two alleles is lost and the remaining allele is mutated [2, 22] . The p53 protein likely functions as a transcription factor [12] , and it has recently been suggested that p53 acts as a cell-cycle-control protein at the level of G1-to S-phase transition [28, 34, 62] . The loss of this function may result in an increased genetic instability [62] .
The loss of heterozygosity of chromosome 17p has been associated with high-grade and high-stage bladder carcinomas [43] . By means of subcloning and sequencing of exons 5-9 of the p53 gene, it has been shown that 17p allelic loss is strongly associated with p53 mutation (nine of ten cases) and that p53 mutation is associated with high-stage disease [49] . The correlation between p53 mutations and stage as well as grade has been confirmed in two other studies using the technique of polymerase chain reaction -SSCP = single-strand conformation polymorphism (PCR-SSCP) [16, 57] . Recently, immunohistochemistry studies have shown p53 overexpression to be correlated with poor survival [33, 47] . In pT1 bladder tumors, Sarkis et al. [47] found a clear correlation between nuclear overexpression of p53 protein and disease progression. The study of Lipponen [33] showed a significant correlation between overexpression and decreased survival for the entire cohort and for muscle-invasive tumors. However, for pTa and pT1 tumors, only a clear trend was found. This discrepancy in the prognostic value found for p53 overexpression in superficial disease might be the result of differences in the antibodies applied and the scoring systems used to quantify p53 overexpression.
In a mutation-analysis study using PCR-SSCR p53 mutations were an unfavorable prognostic factor for the whole group (superficial and invasive tumors) studied [57] . However, when only patients with invasive tumors were taken into consideration, no significant association between the presence of a p53 mutation and a decrease in survival was observed, in contrast to the study of Lippohen [33] . The discordance concerning the prognostic value of p53 mutations and p53 oncoprotein overexpression for the group of invasive TCCs again stresses the dissimilarity of p53 immunohistochemistry and p53 mutation analysis [53] . In the mutation-analysis study, no p53 mutation was found in the superficial tumors, which can be explained by the lack of grade 3 tumors in this group. As grade 3 superficial tumors have the highest probability of progression to invasive disease, the correlation found between p53 mutation, p53 overexpression, and prognosis in this subgroup is of particular interest.
Retinoblastoma gene
Another tumor-suppressor gene shown to be involved in bladder cancer is the retinoblastoma (RB) gene. Restoring the wild-type RB function in an RB-negative cell line (HTB9) resulted in complete suppression of growth in soft agar and decreased tumorigenicity in nude mice, suggesting a key role for the RB gene in bladder cancer [51] .
The RB gene encodes a nuclear phosphoprotein, and several investigators have hypothesized that it functions as a cell-cycle-control protein [20, 31, 59] . Loss of RB function at the protein level occurs in approximately one-third of human bladder tumor cell lines [26] . Gross structural deletions of the RB gene as well as point mutations have been documented in many of these cell lines [25, 26] . More recently, loss of RB protein expression and deletions at the RB locus have been identified in primary bladder cancers, and it has been shown that altered RB expression is correlated with high-grade and high-stage tumors [9, 10, 27, 36, 60] . A high correlation was found between loss of heterozygosity (LOH) at the RB locus and the absence of normal RB protein expression in these tumors [60] . Two immunohistochemistry studies have shown that decreased expression of the RB protein is associated with more aggressive biological behavior [10, 36] . Decreased RB expression was shown to be correlated with shortened survival in the group of invasive tumors. On the basis of current knowledge, it can be concluded that altered RB protein expression may be a prognostic marker of tumor progression in bladder cancer, although the group of superficial tumors remains to be evaluated.
E-cadherin
To metastasize, cancer cells must be released into the blood or lymphatic stream. Decreased intercellular adhesiveness favors the detachment of tumor cells and may play a role in the early steps of the metastatic process. Although cell-cell adhesion is a complex mechanism involving at least four families of adhesion molecules (integrin, immunoglobulin, selectin, and cadherin families), several lines of evidence indicate that CaZ+-dependent, E-cadherinmediated adhesiveness is critically important for epithelial integrity [52] . Modulation of the E-cadherin function of several tumor cell lines either by blocking antibodies or by transfection experiments has revealed an invasion-suppressor role for E-cadherin-mediated cell-cell adhesion in vitro [3, 15, 58] . The correlation between E-cadherin expression and in vitro invasiveness has been tested for three bladder cell lines; the RT4 and RT112 cell lines express E-cadherin and are not invasive, whereas the EJ24 cell line does not express E-cadherin and is invasive [15] . E-cadherin expression has recently been analyzed in 49 bladder tumors with the use of anti-E-cadherin monoclonal antibodies [8] . In this immunohistochemistry study, decreased E-cadherin expression correlated with increased grade and stage and abnormal E-cadherin expression correlated with shorter survival for the whole group studied as well as for the group of invasive tumors. No conclusion can be drawn for the patients with superficial TCC. Therefore, although E-cadherin seems to have potential as a prognostic marker, its precise clinical relevance has to be assessed.
Future directions
This paper discusses the value of genetic alterations in predicting progression of bladder cancer. Presently, only a few markers seem to have potential prognostic value, but their precise clinical relevance has to be studied more extensively. Especially the value of progression markers in superficial TCC needs more attention.
There is clearly a need for new prognostic molecular markers. Many of the areas of chromosomal loss appear to harbor putative tumor-suppressor genes. Once these genes have been identified, a more complete view of the genetic events that determine progression will be obtained. Another possibility in the search for new molecular markers with prognostic value would be to compare different stages of progression at the level of gene expression by means of differential hybridization analyis of cDNA libraries. Since primary tumor material is usually heterogeneous, being composed to subpopulations that are poorly characterized, it is not suitable for the identification of TCC progression markers. Therefore, the identification of such parameters requires a tumor model system in which the different stages of tumor progression are represented. By means of differential hybridization, we are currently investigating a rat bladder-tumor model system (RBT) that phenotypically and cytogenetically resembles human superficial TCC [55] . Thus far we have identified one differentially expressed cDNA clone, identical to ferrtin heavy-chain cDNA, which is thought to play a role as a regulator of cellular differentiation. The tumor line with the highest rate of progression shows the lowest expression of the ferritin heavy-chain gene. Ongoing investigations are testing its value in predicting progression in human bladder cancer. We hope that in the near future a better understanding of the molecular events involved in bladder cancer progression will lead to a system that enables us to identify patients at risk for progression.
